ZNTL Zentalis Pharmaceuticals Inc

Price (delayed)

$1.43

Market cap

$102.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.13

Enterprise value

$96.99M

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of ...

Highlights
The company's debt fell by 9% YoY and by 2.3% QoQ
Zentalis Pharmaceuticals's EPS has decreased by 34% from the previous quarter but it has increased by 6% YoY
The revenue has dropped by 200% year-on-year
ZNTL's gross profit has shrunk by 200% YoY

Key stats

What are the main financial stats of ZNTL
Market
Shares outstanding
71.95M
Market cap
$102.89M
Enterprise value
$96.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$40.56M
Gross profit
-$40.56M
Operating income
-$279.48M
Net income
-$224.19M
EBIT
-$224.15M
EBITDA
-$222.93M
Free cash flow
-$151.63M
Per share
EPS
-$3.13
EPS diluted
-$3.13
Free cash flow per share
-$2.12
Book value per share
$4.11
Revenue per share
-$0.57
TBVPS
$5.36
Balance sheet
Total assets
$384.02M
Total liabilities
$88.64M
Debt
$38.65M
Equity
$295.38M
Working capital
$293.45M
Liquidity
Debt to equity
0.13
Current ratio
6.94
Quick ratio
6.78
Net debt/EBITDA
0.03
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51%
Return on equity
-65.5%
Return on invested capital
-59%
Return on capital employed
-67%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZNTL stock price

How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
2.88%
1 week
6.72%
1 month
10%
1 year
-64.34%
YTD
-52.81%
QTD
23.28%

Financial performance

How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
-$40.56M
Gross profit
-$40.56M
Operating income
-$279.48M
Net income
-$224.19M
Gross margin
N/A
Net margin
N/A

ZNTL financials

The revenue has dropped by 200% year-on-year
ZNTL's gross profit has shrunk by 200% YoY
Zentalis Pharmaceuticals's net income has decreased by 35% from the previous quarter and by 2.4% YoY
The operating income has contracted by 8% from the previous quarter and by 8% YoY

Price vs fundamentals

How does ZNTL's price correlate with its fundamentals

ZNTL Price vs fundamentals

ZNTL Earnings waterfall

ZNTL Price vs fair value

Growth

What is Zentalis Pharmaceuticals's growth rate over time

ZNTL growth chart

Valuation

What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Valuation vs average

Price to earnings (P/E)

Zentalis Pharmaceuticals's EPS has decreased by 34% from the previous quarter but it has increased by 6% YoY

Price to book (P/B)

The P/B is 92% less than the 5-year quarterly average of 4.0 and 43% less than the last 4 quarters average of 0.6
ZNTL's equity is down by 36% YoY and by 12% from the previous quarter

Price to sales (P/S)

The revenue has dropped by 200% year-on-year

Efficiency

How efficient is Zentalis Pharmaceuticals business performance
The ROE has dropped by 51% since the previous quarter and by 42% year-on-year
ZNTL's ROIC has dropped by 51% since the previous quarter and by 20% year-on-year
The ROA is down by 48% since the previous quarter and by 35% year-on-year

Dividends

What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZNTL.

Financial health

How did Zentalis Pharmaceuticals financials performed over time

Assets vs liabilities

The total assets has contracted by 31% YoY and by 11% from the previous quarter
The current ratio has decreased by 24% YoY and by 5% from the previous quarter

Debt vs equity

The company's debt is 87% lower than its equity
The debt to equity has grown by 44% year-on-year and by 8% since the previous quarter
ZNTL's equity is down by 36% YoY and by 12% from the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.